Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal amount of convertible senior notes due 2033 (the "Convertible Notes"). The Company also expects to grant a 13-day option to the initial purchasers to purchase up to an additional $150 million aggregate principal amount of the Convertible Notes. The Convertible Notes are to be offered and sold only to persons reasonably believed to be "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").